Romidepsin
Kostmann's Neutropenia
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2/3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Kostmann's Neutropenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →